Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics.
Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics.
复制标题
DOI：
10.1186/s13052-021-00980-2
复制
发表时间：
2021-02-08
影响因子：
3.6
通讯作者：
Rheumatology Study Group of the Italian Society of Pediatrics
中科院分区：
文献类型：
--
作者：
Cattalini M;Taddio A;Bracaglia C;Cimaz R;Paolera SD;Filocamo G;La Torre F;Lattanzi B;Marchesi A;Simonini G;Zuccotti G;Zunica F;Villani A;Ravelli A;Rheumatology Study Group of the Italian Society of Pediatrics
意大利是第一个遭受 SARS-CoV-2 疫情袭击的西方国家。现在越来越多的证据表明，少数感染 SARS-CoV2 的儿童可能会出现严重的多系统炎症综合征，称为与 2019 年冠状病毒病相关的多系统炎症综合征 (MIS-C)。迄今为止，还没有针对这种疾病的普遍认可的方法。由于意大利现在面临第二波 COVID-19 病例，我们担心 MIS-C 病例会再次出现。因此，我们决定准备一份报告，帮助临床医生应对这种新颖且具有挑战性的疾病。我们提出了一种诊断算法，以帮助病例定义和指导检查，以及一种治疗方法。应根据全身炎症的存在和特定器官受累情况及时识别 MIS-C。早期治疗至关重要，根据疾病的严重程度，联合使用皮质类固醇、大剂量免疫球蛋白和抗细胞因子治疗。还将讨论辅助治疗（例如阿司匹林和血栓预防）。我们提出了一份文件，将帮助医生诊断和治疗 MIS-C 患者。鉴于现有证据的水平和所使用的方法，本文件不应被解释为指南；关于最佳治疗的最终决定仍应由护理医生根据个人情况做出。
Italy was the first Western country to be hit by the SARS-CoV-2 epidemic. There is now mounting evidence that a minority of children infected with SARS-CoV2 may experience a severe multisystem inflammatory syndrome, called Multisystem inflammatory Syndrome associated with Coronavirus Disease 2019 (MIS-C). To date no universally agreed approach is available for this disease. as Italy is now facing a second hity of COVID-19 cases, we fear a recrudescence of MIS-C cases. We have, therefore, decided to prepare a report that will help clinicians to face this novel and challenging disease. We propose a diagnostic algorithm, to help case definition and guide work-up, and a therapeutic approach. MIS-C should be promptly recognized, based on the presence of systemic inflammation and specific organ involvement. Early treatment is crucial, and it will be based on the combined use of corticosteroids, high-dose immunoglobulins and anti-cytokine treatments, depending on the severity of the disease. Ancillary treatments (such as. aspirin and thrombo-profilaxis) will be also discussed. we propose a document that will help physicians to diagnose and treat MIS-C patients. Given the level of evidence available and the methodology used, this document should not be interpreted as a guideline; the final decision about the optimal management should still be taken by the caring physician, on an individual basis.
登录
查看更多内容
影响因子：
3.4
作者：
Mahajan R;Lipton M;Broglie L;Jain NG;Uy NS
通讯作者：
Uy NS
基于共识的临床建议和研究优先级，用于住院的儿童抗凝血栓预防症，因1909999名相关疾病而住院。
DOI：
10.1111/jth.15073
发表时间：
2020-11
期刊：
Journal of thrombosis and haemostasis : JTH
影响因子：
--
作者：
通讯作者：
--
影响因子：
37.8
作者：
McCrindle, Brian W.;Rowley, Anne H.;Pahl, Elfriede
通讯作者：
Pahl, Elfriede
影响因子：
19
作者：
Belot, Alexandre;Antona, Denise;Levy-Bruhl, Daniel
通讯作者：
Levy-Bruhl, Daniel
影响因子：
8
作者：
Licciardi, Francesco;Pruccoli, Giulia;Montin, Davide
通讯作者：
Montin, Davide